Lymphokine-activated killer cell therapy combined with high-dose glucocorticoid showed clinical efficacy towards advanced lung carcinoma

Anticancer Research

Volumn 30, Issue 8, 2010, Pages 3125-3128

  Kato, Mikio ^a   Goto, Shigenori ^b   Soma, Gen Ichiro ^c,d,e,f  

^a Hanakoganei Clinic   (Japan)

^b Seta Clinic Group   (Japan)

^c TOKUSHIMA BUNRI UNIVERSITY   (Japan)

^d Research and Development Department Macrophi Inc   (Japan)

^e TOKYO UNIVERSITY OF SCIENCE   (Japan)

^f KAGAWA UNIVERSITY   (Japan)

Author keywords

CEA; Combination therapy; Inflammation; Micrometastases; Postsurgical

Indexed keywords

BETAMETHASONE; CISPLATIN; GEFITINIB; PACLITAXEL; PREDNISOLONE;

ADULT; ANAMNESIS; ARTICLE; CANCER STAGING; CASE REPORT; CELL THERAPY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; GASTROINTESTINAL HEMORRHAGE; HUMAN; LOBECTOMY; LUNG ADENOCARCINOMA; LUNG DISEASE; LUNG METASTASIS; LYMPHANGITIS; LYMPHOKINE ACTIVATED KILLER CELL; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PULMONARY LYMPHANGITIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ADENOCARCINOMA; DOSE RESPONSE; IMMUNOLOGY; LUNG TUMOR; METASTASIS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY;

ADENOCARCINOMA; BETAMETHASONE; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; KILLER CELLS, LYMPHOKINE-ACTIVATED; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; TREATMENT OUTCOME;

EID: 77957370142     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, Shimada K, Sakamoto M, Hirohashi S, Ohashi Y and Kakizoe T: Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 356: 802-807, 2000.
2. June CH: Adoptive T-cell therapy for cancer in the clinic. J Clin Invest 117: 1466-1476, 2007. (Pubitemid 46871329)
3. Mazumder A and Rosenberg SA: Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2. J Exp Med 159: 495-507, 1984.
4. Choi KS, Song EK and Yim CY: Cytokines secreted by IL-2-activated lymphocytes induce endogenous nitric oxide synthesis and apoptosis in macrophages. J Leukoc Biol 83: 1440-1450, 2008.
5. Griffith TS, Wiley SR, Kubin MZ, Sedger LM, Maliszewski CR and Fanger NA: Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. J Exp Med 189: 1343-1354, 1999.
6. Hagemann T, Biswas SK, Lawrence T, Sica A and Lewis CE: Regulation of macrophage function in tumors: the multifaceted role of NF-kappaB. Blood 113: 3139-3146, 2009.
7. Ngo-Metzger Q, Phillips RS and Mc Carthy EP: Ethnic disparities in hospice use among Asian-American and Pacific Islander patients dying with cancer. J Am Geriatr Soc 56: 139-144, 2008.
8. + T-cells. J Immunother 28: 517-524, 2005.
9. Banciu M, Metselaar JM, Schiffelers RM and Storm G: Antitumor activity of liposomal prednisolone phosphate depends on the presence of functional tumor-associated macrophages in tumor tissue. Neoplasia 10: 108-117, 2008.
10. Biswas SK, Gangi L, Paul S, Schioppa T, Saccani A, Sironi M, Bottazzi B, Doni A, Vincenzo B, Pasqualini F, Vago L, Nebuloni M, Mantovani A and Sica A: A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). Blood 107: 2112-2122, 2006.
11. Ohno S, Ohno Y, Suzuki N, Kamei T, Koike K, Inagawa H, Kohchi C, Soma G and Inoue M: Correlation of histological localization of tumor-associated macrophages with clinicopathological features in endometrial cancer. Anticancer Res 24: 3335-3342, 2004.
12. Kawai O, Ishii G, Kubota K, Murata Y, Naito Y, Mizuno T, Aokage K, Saijo N, Nishiwaki Y, Gemma A, Kudoh S and Ochiai A: Predominant infiltration of macrophages and CD8(+) T-cells in cancer nests is a significant predictor of survival in stage IV non-small cell lung cancer. Cancer 113: 1387-1395, 2008.
13. + myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 11: 6713-6721, 2005. (Pubitemid 41339014)
14. Chiarella P, Vulcano M, Bruzzo J, Vermeulen M, Vanzulli S, Maglioco A, Camerano G, Palacios V, Fernandez G, Brando RF, Isturiz MA, Dran GI, Bustuoabad OD and Ruggiero RA: Anti-inflammatory pretreatment enables an efficient dendritic cell-based immunotherapy against established tumors. Cancer Immunol Immunother 57: 701-718, 2008.